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Background.   Familial dilated cardiomyopathy (DCM) can be caused by mutations in the 
proteins of the muscle thin filament.  In vitro these mutations decrease Ca2+-sensitivity and 
crossbridge turnover rate but the mutations have not been investigated in human tissue.  We 
have studied the Ca2+-regulatory properties of myocytes and troponin extracted from the 
explanted heart of a patient with inherited DCM due to the cTnC G159D mutation. 
Methods and results.    Mass spectroscopy showed that the mutant cTnC was expressed 
approximately equimolar with wild-type cTnC.   Contraction was compared in skinned 
ventricular myocytes from the cTnC G159D patient and non-failing donor heart.  Maximal   
Ca2+-activated force was similar in cTnC G159D and donor myocytes but the Ca2+-sensitivity 
of cTnC G159D myocytes was higher (EC50 G159D/donor = 0.59).  Thin filaments 
reconstituted with skeletal muscle actin and human cardiac tropomyosin and troponin were 
studied by in vitro motility assay. Thin filaments containing the mutation had a higher Ca2+-
sensitivity (EC50 G159D/donor = 0.36±0.07) whilst the maximally activated sliding speed was 
unaltered.  In addition, the cTnC G159D mutation blunted the change in Ca2+ sensitivity when 
TnI was dephosphorylated.  With wild-type troponin, Ca2+-sensitivity was increased (EC50 
P/unP = 4.7±1.9) but not with cTnC G159D troponin (EC50 P/unP = 1.2±0.2). 
Conclusions.    We propose that uncoupling of the relationship between phosphorylation and 
Ca2+-sensitivity could be the cause of the DCM phenotype.  The differences between these 
data  and previous in vitro results show that native phosphorylation of troponin I and troponin 
T and other post-translational modifications of sarcomeric proteins strongly influence the 
functional effects of a mutation. 
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INTRODUCTION 
 Dilated cardiomyopathy (DCM) is a common cause of sudden death and heart failure 
and it is estimated that 20-30% of cases of DCM are caused by mutations in specific 
proteins1. Many cases of inherited ‘pure’ DCM that are not associated with other symptoms, 
such as conduction disease, are caused by mutations in contractile proteins including actin, 
myosin, tropomyosin and all three subunits of troponin 1, 2.  These cardiomyopathy-causing 
mutations present a unique opportunity to link genotype with phenotype.  Since mutations at 
different sites in several different contractile proteins can produce a single phenotype it has 
been proposed that mutations causing the same phenotype alter the contractile mechanism in 
the same way. In support of this hypothesis, a number of DCM mutations have been shown to 
cause decreased Ca2+-sensitivity linked to reduced troponin C Ca2+-binding affinity and 
decreased cross-bridge turnover rate in vitro3-9. However, recent work, studying both 
recombinant proteins and intact myofibrils, has given results that contradict the simple 
hypothesis and this raises doubts about the physiological relevance of the early studies 10-13. 
It has been noted previously that the functional effect of cardiomyopathic mutations in 
sarcomeric proteins depends upon a number of extrinsic factors.  Predominant amongst these 
are the level of expression of the mutant protein  the species and isoform of the partner 
proteins used in reconstituted systems 4,14 and the post-translational modifications, 
particularly phosphorylation, of both the mutated and the partner proteins11, 15-19.  These 
factors are often unknown and all of them are difficult to reproduce in the synthetic systems 
currently studied.  Consequently, unravelling the links between genotype and phenotype in 
familial cardiomyopathies demands study of myopathic human cardiac tissue.  The 
availability of such material from septal myectomy operations on hypertrophic 
cardiomyopathy (HCM) patients has yielded some information about phenotype-genotype 
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relationships in MYH7 and MYBPC3 mutations 20-24, but no studies have been reported on 
familial dilated cardiomyopathy mutations. 
In this manuscript we report the first functional investigation of cardiac myocytes and 
isolated troponin from the explanted heart of a patient with familial dilated cardiomyopathy 
due to the mutation of glycine 159 to aspartic acid in troponin C (TNNC1 gene) 25.  This is the 
only DCM-causing mutation that has been found in TNNC11 and as a result it has been 
extensively investigated in vitro.  In experiments using filaments reconstituted from 
recombinant proteins the mutation has been shown to cause the typical DCM molecular 
phenotype of reduced Ca2+-sensitivity and slower cross-bridge turnover 8, 9 but, interestingly, 
there is already evidence from studies using recombinant troponin C exchanged into more 
organised systems such as skinned skeletal or cardiac muscle fibres that the effects of this 
mutation on muscle function depend upon partner proteins and upon their phosphorylation 
levels 11, 19, 26.  We have obtained a tissue sample from a patient with this mutation, and have 
therefore been able to investigate this disease-causing mutation in a completely native 
context. This has enabled us to clarify the basic mechanism by which this mutation, and by 
analogy other DCM-causing mutations, may cause dilated cardiomyopathy in man. 
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METHODS 
Human heart muscle samples 
The TNNC1 G159D mutation associated with DCM was identified in a single family by 
Mogensen et al1.  A 3-year old child from this family presented with DCM (LVEDD 54mm, 
LVESD 50mm, EF 20%) and was given a heart transplant.  This case has been described in 
detail by Kaski et al. 25. The explanted heart muscle was cut into 0.5g pieces, was rapidly 
frozen in liquid nitrogen and stored for further analysis. Local ethical approval was obtained 
from University College London Hospitals and the Brompton, Harefield & NHLI ethics 
committees for collection and use of tissue samples.  The investigation conformed with the 
principles outlined in the Declaration of Helsinki.  Control heart muscle from 4 non-failing 
donor hearts was supplied by Prof. C Dos Remedios, University of Sydney, Australia.  Ethical 
approval was obtained from The Brompton, Harefield & NHLI Research Ethics Committee, 
London and St Vincent’s Hospital, Sydney. The donor heart tissue was obtained from hearts 
where no suitable transplant recipient was found.  The donor patients had no history of 
cardiac disease, a normal cardiac examination, normal ECG and normal ventricular function 
on echocardiography within 24 hours of heart explantation.  Clinical and functional 
characteristics of the donor heart samples have been previously reported 27. 
Skinned myocytes 
Skinned myocyte experiments were carried out as described previously 28, with minor 
modifications noted below. In brief, on the day of use, a section of the human tissue sample 
was removed from storage in liquid nitrogen and was thawed at 4oC in Ca2+-free relaxing 
solution containing protease inhibitors (Roche Complete Mini protease inhibitor cocktail 
tablets, 100µg/L). The tissue was homogenised in a mechanical blender, resulting in a 
suspension of single myocytes, cell fragments and small groups of cells. Myocytes were 
 6 
permeabilised by treatment with relaxing solution containing 1% Triton X-100 for 15 min. 
The myocyte pellet was washed three times in relaxing solution and stored on ice for up to 10 
hours.  
A single myocyte was attached between a force transducer and a high-speed servomotor with 
silicone glue 29 and was stretched to a resting sarcomere length of 2.0 µm. Myocytes were 
gravity-superfused using a 3-barrel pipette attached to a stepper motor 30. Isometric force was 
measured as the difference between the steady force during Ca2+ activation and the zero force 
reached during the period when the myocyte was made slack during activation by rapid 
shortening the myocyte by 20% for 40 ms. All measurements were made at 15°C. To 
determine the Ca2+-sensitivity of force, isometric force measured in each submaximal Ca2+-
activation solution was expressed as a fraction of maximal Ca2+-activated force (determined at 
30 µmol/L Ca2+). The force – [Ca2+] relationship data for each myocyte was fitted by a 
modified Hill equation. Maximal force was normalised to cross-sectional area. Cross-
sectional was calculated using the width and depth of the myocyte assuming that the cell had 
an oval cross-section. 
Human cardiac troponin 
Human cardiac troponin was prepared from heart myofibrils using an anti-TnI antibody 
affinity column as described by Messer et al 27. Phosphorylation of troponin I and troponin T 
was measured in SDS-PAGE using Pro-Q Diamond phosphoprotein specific stain as 
described previously 27.  Troponin was dephosphorylated by treatment with acid phosphatase 
27.  Ca2+-regulation of thin filaments containing human cardiac troponin was studied using the 
quantitative in vitro motility assay.  These techniques have been previously described 20, 27. 
Mass spectroscopy 
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Surface-Enhanced Laser Desorption/Ionization (SELDI) mass spectrometry was used to 
analyse G159D cTnC expression in affinity purified troponin from human heart tissue.  
Recombinant wild-type and G159D cTnC and troponin extracted from the tissue sample were 
dissolved in 8mol/L urea, 2mmol/L EDTA and applied to NP20 ProteinChips.  The chips 
were rinsed with water to wash away salt and non-binding impurities and 2 x 1µL of a 50% 
saturated solution of sinapinic acid in 50% acetonitrile, 0.5% trifluoroacetic acid applied.  The 
chips were read in a PBS IIc SELDI-TOF (Ciphergen, UK) calibrated with bovine insulin, 
ubiquitin, cytochrome C, myoglobin and serum albumin (Sigma, UK).   
Statement 
The authors had full access to the data and take responsibility for its integrity. All authors 
have read and agree to the manuscript as written. 
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RESULTS 
Identification and characterisation of troponin with TnC G159D mutation. 
The presence of the G159D cardiac troponin C (cTnC) mutation in troponin isolated from the 
patient sample was confirmed by SELDI mass spectroscopy (Figure 1).  SELDI-MS analysis 
of pure recombinant wild-type cTnC generated a peak at m/z 18,410 whilst the G159D cTnC 
generated a peak at m/z 18,462 (Figure 1A).  These peaks represent singly charged cTnC ions 
(calculated molecular weights for wt and G159D cTnC being 18402 and 18460 respectively).  
Spectra of the affinity purified heart troponin showed major peaks at m/z ~18500, 24000 and 
34600 consistent with singly charged ions of cTnC, TnI and TnT respectively (Figure 1B). 
Closer examination of the cTnC peak(s) of the troponin isolated from the patient’s heart 
muscle clearly showed the presence of two cTnC components with different m/z values. 
These two components are separated by approximately m/z 60 (m/z 18,424 and 18,484) 
consistent with the 58 Da increase in mass introduced by the glycine to aspartic acid mutation 
and hence correspond to normal and G159D cTnC (Figure 1A). 
We observed that recombinant cTnC and G159D cTnC spectra were additive in mixtures (see 
supplemental data B) therefore we could estimate the fraction of mutated cTnC in the muscle 
sample by comparison with synthetic spectra of mixtures at varying ratios.  Figure 1C shows 
that the best fit was obtained with 55% G159D cTnC in the patient heart muscle troponin 
sample. 
The contractile protein composition of myofibrils and isolated troponin from donor and 
G159D cTnC hearts were indistinguishable, in particular, the troponin C content of myofibrils 
was the same in all the samples we examined (Figure 2A).  Comparison of phosphorylation of 
MyBP-C, troponin T, troponin I and MLC-2 in myofibrils showed no significant difference 
between donor and patient troponin (Figure 2A),  whilst comparison of phosphorylation of 
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troponin I and T in SDS-PAGE of isolated troponin likewise showed no differences between 
donor and G159D cTnC samples (Figure 2B). 
Contractility of skinned myocytes 
We investigated the myofilament-based contractile function in human skinned ventricular 
myocytes prepared from 4 control (unused donor) hearts and from the G159D cTnC patient. 
We found no visible difference in the sarcomeric structure between skinned donor and G159D 
cTnC myocytes.  A range of submaximal Ca2+ activating solutions was used to determine 
myofibrillar Ca2+-sensitivity. There was consistency between the force-pCa curves in several 
myocytes from each patient and there was no difference in mean EC50 values between the 4 
donor patients (P = 0.11; one-way ANOVA). The data from all donor patients was therefore 
combined to give the average force-pCa curve for skinned human donor myocytes (Figure 
3A). We found that the Ca2+-sensitivity of G159D cTnC myocytes was significantly greater 
than for donor myocytes (Figure 3A, Table 1), with mean tension EC50 values of 0.49 ± 0.04 
µmol/L (n=9 myocytes) and 0.80 ± 0.04 µmol/L (n=22), respectively (P<0.001, unpaired t-
test). The steepness of the force-Ca2+ relationship was also lower in human G159D cTnC than 
in donor myocytes, with Hill n values of 1.76 ± 0.12 and 2.99 ± 0.18, respectively (P<0.001, 
unpaired t-test). As shown in Figure 3B, maximum force was found to be similar in G159D 
cTnC and donor myocytes (P = 0.66, unpaired t-test). 
Thin filament regulation measured by in vitro motility assay 
Thin filaments containing human cardiac troponin and tropomyosin were studied. G159D 
cTnC and donor troponin were equally effective at regulating actin-tropomyosin filaments in 
the in vitro motility assay.  At low [Ca2+] (1 nmol/L) the thin filament motility for both 
G159D cTnC and donor troponin was switched off by 40nmol/L troponin, with the fraction 
motile falling to approximately 0.05.  The sliding speed was reduced by 35±5% for G159D 
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cTnC troponin and 38±7% for donor troponin (means of 7 preparations, p=0.75 in paired t-
test).  At high [Ca2+] (3.9 µmol/L), 40nmol/L human cardiac troponin increased sliding 
speeds by 7% over actin-tropomyosin as has been previously observed 31.  In these 
experiments the increase was not statistically significant and there was also no significant 
difference between G159D cTnC and donor troponin (results not shown).  The mean fraction 
motile at high Ca2+ was not significantly different for the two troponin species (G159D 
cTnC= 0.83±0.04; donor =0.82±0.05, n=7, P = 0.61).  Sliding speed was similarly unaffected 
by the presence of the mutant cTnC (P = 0.92). 
When we measured Ca2+-sensitivity of thin filaments reconstituted with G159D cTnC and 
donor troponin we found the Ca2+-sensitivity of thin filaments containing G159D cTnC 
troponin was higher than donor for both the fraction motile and sliding speed parameters 
when they were compared in the same dual chamber motility cell.  As previously found with 
this assay method, there was considerable variation in the absolute value of EC50 between 
assays with different troponin, myosin and actin preparations, but paired measurements in the 
same motility cell always produced a consistent difference between G159D cTnC and donor 
troponin.  In the example in Figure 4, showing the results from one troponin preparation, the 
G159D cTnC curve was shifted to the left and the calculated Ca2+-sensitivity was 4.4-fold 
higher than donor troponin.  The results from three pairs of troponin preparations, shown in 
supplemental data A1 and summarised in table 1, confirm the higher Ca2+-sensitivity with the 
mutant troponin with the mean ratio EC50 G159D/donor for fraction motile = 0.36±0.07 and 
sliding speed= 0.12±0.03).  The calculated Hill coefficient was very variable and was not 
significantly different between G159D cTnC and donor troponin (mean nH=1.4±0.2, n=12, all 
assays pooled).   
 
 11 
The effect of changing troponin phosphorylation levels 
Troponin I and troponin T were natively phosphorylated in G159D cTnC and donor troponin 
(Figure 2) but our previous studies with this mutation used unphosphorylated recombinant 
troponin 8.  Therefore we determined the effect of complete dephosphorylation of troponin 
using acid phosphatase.  Figure 5 shows two typical measurements.  With donor troponin we 
observed higher Ca2+-sensitivity and decreased sliding speed with dephosphorylated troponin 
as previously reported27.  In contrast, native and dephosphorylated G159D cTnC troponins 
exhibited similar Ca2+ sensitivities and there was no significant effect of dephosphorylation 
on the maximum sliding speed.  Thus the dephosphorylated G159D cTnC- containing thin 
filaments were not responsive to the phosphorylation change shown by the donor troponin.  In 
pooled data from paired measurements with three troponin preparations EC50 G159D cTnC/ 
G159D cTnC dP was 1.24±0.17, p=0.29.  When dephosphorylated G159D cTnC and donor 
troponins were compared directly in paired experiments, the Ca2+-sensitivity of G159D cTnC 
remained greater than donor (EC50 G159 cTnC dP/donor dP = 0.56±0.09, n=2, Table 1 and 
supplemental data A2). 
The effect of changing tropomyosin 
Previous studies using unphosphorylated recombinant proteins showed a lower Ca2+-
sensitivity with G159D cTnC as well as with other DCM mutations in troponin T and 
tropomyosin8.  In contrast, the patient sample of G159D cTnC  troponin exhibited a higher 
Ca2+-sensitivity than donor cTnC,  when studied using native human troponin and 
tropomyosin, and its Ca2+-sensitivity was independent of phosphorylation (Table 1, Figures 
3,4,5).  To test whether this effect is related to partner proteins, we substituted the native 
human cardiac tropomyosin used in these studies with a recombinant α-tropomyosin 
expressed in E.coli with an N-terminal Ala-Ser extension to compensate for the absence of the 
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native N-terminal acetylation (AS-α-tropomyosin) 32.  Recent studies show this tropomyosin 
species is functionally different from native cardiac tropomyosin 12.  In the presence of AS-α-
tropomyosin we observed a 2.6-fold lower Ca2+-sensitivity with G159D cTnC troponin 
compared with donor troponin, similar to previous experiments using recombinant troponin 




Mutations that cause familial dilated cardiomyopathy without complications, such as 
conduction disease, have been found in most of the proteins of the cardiac muscle sarcomere, 
however only one DCM-associated mutation has so far been identified in TNNC1 1.  The 
cTnC G159D mutation was found in a single family and genotypes were obtained over five 
generations.  This appears to be a particularly malignant mutation, since every individual with 
the mutation has been affected and in particular the individual studied here required a heart 
transplant at age 3 25.  Despite the young age of the patient the tissue sample contained adult 
isoforms of contractile proteins and contractile protein phosphorylation levels 
indistinguishable from adult donor heart (Figure 2) 1.   The mechanism by which mutations in 
thin filament proteins cause DCM has been extensively studied using recombinant proteins 
and a consistent pattern of decreased Ca2+-sensitivity and slower crossbridge turnover has 
emerged 8, 33.  This manuscript reports the first study of mutated troponin from human heart 
and it is evident that the functional effects of the mutation are quite strikingly different from 
the same mutation studied in synthetic systems.   
Mass spectroscopy of the troponin from the heart muscle sample shows clearly that the cTnC 
G159D mutation predicted from genetic studies is expressed in heart as about half of total 
cTnC (Figure 1) and SDS-PAGE  indicates normal levels of all three troponin subunits in the 
isolated troponin we have studied (Figure 2),  therefore it is likely that the G159D cTnC 
mutation acts as a poison peptide by changing thin filament regulation.  In functional 
measurements at both the myocyte and myofilament level the mutation causes an increase in 
Ca2+-sensitivity with no change in crossbridge turnover rate, as assessed by the maximum 
sliding speed (Figures 3,4, Table 1).  These findings are opposite to that previously found 
with recombinant DCM mutations, where Ca2+-sensitivity and crossbridge turnover rate were 
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found to be decreased 34.  Increased Ca2+-sensitivity is a characteristic of mutations associated 
with hypertrophic cardiomyopathy 9, but the patient showed no symptoms of hypertrophy 
preceding heart failure and this mutation has been consistently linked to the DCM phenotype 
1, 25.  Thus this unique study of a DCM mutation obtained from patient muscle is not 
consistent with the experiments using equivalent mutant recombinant proteins.  These 
paradoxical results seem to suggest that previous in vitro experimentation, implicating an 
association of lower Ca2+-sensitivity and crossbridge turnover rate with the DCM phenotype 
may be incorrect.  It is interesting to note that an investigation of DCM-causing mutations in 
α-tropomyosin also concluded that decreased Ca2+-sensitivity may not be the primary trigger 
for the DCM phenotype12. 
Recent evidence suggests that defects in the modulation of Ca2+-sensitivity by troponin I 
phosphorylation may play a significant role in the mechanism of inherited DCM.   In a study 
of a DCM-causing mutation in cardiac actin (ACTC E361G) expressed in a transgenic mouse 
we have found that the only difference between the transgenic and non-transgenic mouse was 
that the relationship between Ca2+-sensitivity and troponin phosphorylation was uncoupled in 
the transgenic mouse 16.  In donor heart troponin, Ca2+-sensitivity was increased when the 
troponin was dephosphorylated, however we found that Ca2+-sensitivity in the G159D cTnC  
troponin was almost independent of the level of troponin phosphorylation (Figure 5, Table 1).  
Therefore, by analogy with the ACTC E361G study, we could propose that the uncoupling of 
the relationship between phosphorylation and Ca2+-sensitivity is the primary cause of this 
DCM phenotype, at least for this mutation.  This provides a novel mechanism for initiation of 
DCM; if thin filaments do not respond to PKA phosphorylation, the contractile response to β-
adrenergic stimulation (increased relaxation rate and power output) will be blunted.  This 
would cause cardiac relaxation rate and contractile reserve to be reduced in the same way as 
they are in acquired heart failure, where troponin I becomes dephosphorylated, resulting in a 
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higher than normal Ca2+-sensitivity 27, 35, 36.  The combination of high Ca2+-sensitivity, which 
has not been seen with other DCM-causing mutations10, 13, 16, and blunted response to 
adrenergic stimulation may account for the severity and early onset of DCM with the G159D 
cTnC mutation 1, 25. 
 The findings from this human biopsy study of G159D cTnC are compatible with recently 
published animal studies that used recombinant G159D cTnC in skinned muscle 11, 19.   
Biesiadecki et al. reported that G159D cTnC specifically blunted the phosphorylation-induced 
decrease in Ca2+-sensitive tension development, without altering the increase in cross-bridge 
cycling, when the mutant troponin was exchanged into rat heart trabeculae.  Moreover, 
measurements of Ca2+ binding by TnI-TnC complexes in vitro have shown that the 
dependence of Ca2+ binding affinity on troponin I phosphorylation was lost in the presence of 
the G159D cTnC mutation 11, 37.  
In contrast to the results from G159D cTnC using native troponin, reported here, this 
mutation previously produced a decrease in Ca2+-sensitivity or Ca2+ affinity when tested with 
recombinant troponin subunits 8, 9 .  We also found a lower Ca2+-sensivity with native 
troponin containing G159D cTnC when we used recombinant AS-α-tropomyosin in place of 
native human tropomyosin (Figure 6, Table 1).  These findings emphasise the importance of 
studying the subtle functional consequences of cardiomyopathy-causing mutations in a native 
context.  We have already shown that the effect of a mutation depends on the fraction of 
mutant protein present and also on the species origin of partner proteins 14.  The current work 
emphasises that phosphorylation of troponin I and troponin T and post-translational 
modifications of tropomyosin may strongly influence the functional effect of a mutation38.  It 
is therefore vitally important to conduct experiments in as near-native conditions as possible 
and also, when possible, to check in vitro experiments against the results obtained using 
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native tissue from patients with the corresponding cardiomyopathy.  
Could uncoupling of the TnI phosphorylation effect on EC50 be a common mechanism of 
familial DCM?  We have shown that this mechanism explains the G159D data and it is also a 
likely explanation for the results from the ACTC E361G transgenic mouse 6.   In addition the 
hypothesis is not incompatible with published work, since the relationship between the effect 
of a mutation and troponin phosphorylation has not yet been tested with human sequence 
actin, tropomyosin and troponin for any other DCM mutations 8-10,12,13.  
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TABLE 1 LEGEND 
Effect of the TNNC1 G159D mutation on Ca2+-sensitivity of thin filaments from patient 
muscle and in reconstituted systems, measured by in vitro motility assay. 
 
Footnotes: 
Due to variability between preparations of troponin, actin and myosin comparisons can only 
be made within an experiment (rows) and not between experiments (columns). 





Figure 1 Detection and quantification of G159D cTnC by SELDI-MS 
A) SELDI-MS spectra of troponin C. Normalised peak signal intensity is plotted against mass 
to charge (m/z) ratio. Overlaid spectra of i) recombinant native cTnC (green), ii) recombinant 
G159D cTnC (blue) and iii) G159D cTnC human cardiac troponin sample (black). 
B) Spectrum of whole human troponin (see figure 2B for SDS-PAGE of this troponin 
sample). Peaks are seen for troponin C (m/z 18,495), troponin I (m/z 23,956) and troponin T 
(34,566 m/z).  For comparison spectra of TnC mixtures of cTnC and cTnC cG159D are 
shown in the supplemental data section B. 
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C) Comparison of the G159D cTnC human cardiac troponin spectrum (thick red line) with 
synthetic spectra containing 50% G159D cTnC (black), 55% G159D cTnC (blue), 60% 
G159D cTnC (green) and 70% G159D cTnC (purple).  
 
Figure 2.   Comparison of protein content and phosphorylation of native and G159D 
cTnC mutant myofibrils and purified troponin 
A)  Myofibrils from donor and G159D cTnC heart muscle stained with Flamingo pink total 
protein stain and with Pro-Q Diamond phosphoprotein stain.  The troponin C content of 
myofibrils was the same in all the samples we examined (ratio band volume TnC/MLC-2 = 
0.353±0.004 for donor heart myofibrils and 0.355±0.006 for G159D TnC myofibrils, n=5).  
Phosphorylation levels were also the same in donor and G159D cTnC myofibrils:  mean Pro-
Q Diamond/Flamingo Pink band volumes for 5 samples were as follows:  MyBP-C,  
donor=0.488±0.018, G159D cTnC = 0.489±0.038;  Troponin T, donor=0.634±0.08, G159D 
cTnC = 0.570±0.046;  Troponin I, donor 1.19±0.03, G159D cTnC = 1.34±0.04;  MLC-2,  
donor=0.147±0.023,  G159D cTnC = 0.132±0.017 
B)  Purified troponin from donor and G159D cTnC heart muscle stained with Coomassie Blue 
and Pro-Q Diamond.  TnI and TnT are phosphorylated.  The level of phosphorylation was 
measured by comparison with the pure TnI standard.  The mean TnI phosphorylation was 
2.03±0.01 molPi/mol in donor and 2.23±0.01 in G159D cTnC and mean TnT phosphorylation 
was 2.83±0.01 molPi/mol in donor and 2.74±0.02 in G159D cTnC (n=7)  
 
Figure 3. Contractile properties of skinned donor and G159D cTnC myocytes. 
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Ca2+-sensitivity of isometric force. Submaximal forces in each myocyte were expressed 
relative to the maximum force (at 30 µmol/L Ca2+) in the same myocyte. Data are from 4 
donor hearts (21 cells) and the G159D cTnC mutant heart (8 cells). Error bars indicate S.E.M. 
Inset: Maximum force in skinned myocytes from human donor (open bar) and G159C cTnC 
tissue (filled bar).  
 
Figure 4  Comparison of Ca2+- activation of motility of thin filaments reconstituted with 
native donor or native G159DcTnC troponin. 
Donor and G159D cTnC troponin were compared in the same motility cell.  Sliding speed 
(top ) and fraction of filaments motile (bottom) derived from the same motility experiment.   
Points are mean and standard error of 4 measurements made in a single motility cell. ❍ and 
dotted line, native donor thin filaments. Hill equation fits to sliding speed:   
EC50=0.074±0.134 µmol/L, nH = 5.9±2.0, fraction motile: EC50=0.044±0.002 µmol/L, nH= 
1.38±0.06.  ● and solid line, G159D cTnc thin filaments. Hill equation fits to sliding speed: 
EC50=0.019±0.093 µmol/L, nH= 9.2±20, fraction motile:  EC50=0.010±0.010 µmol/L, nH= 
2.9±6.2. 
 
Figure 5  Effect of dephosphorylation on Ca2+-sensitivity measured by IVMA with 
donor or G159D cTnC troponin 
Donor and G159D cTnC were assayed in separate experiments.  Points shown are mean and 
standard error of 4 measurements made in a single motility cell.   
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A  Donor heart troponin.  ❍  native troponin,  ❏ dephosphorylated troponin. 
B  G159D cTnC troponin.  ● native troponin, ■ dephosphorylated troponin.  
C  Table showing calculated fits of the data to the Hill equation. 
D  SDS-PAGE of native and dephosphorylated troponin stained with Pro-Q Diamond 
showing that TnT and TnC are fully dephosphorylated by acid phosphatase treatment. 
 
Figure 6  Ca2+-sensitivity of thin filaments reconstituted with AS α-tropomyosin and 
donor or G159D cTnC troponin 
The figure shows the sliding speed (top) and fraction of filaments motile (bottom) derived 
from the same motility experiment.   Points are mean and standard error of 4 measurements 
made in a single motility cell. ❍ and dotted line, thin filaments containing AS-α-tropomyosin 
and donor troponin.  Hill equation fits to fraction motile: EC50=0.149±0.031 µmol/L, nH= 
1.2±0.2,  sliding speed:   EC50=0.120±0.081 µmol/L, nH= 5.5±4.6.     ● and solid line, thin 
filaments containing AS-α tropomyosin and G159D cTnC troponin. Hill equation fits to 
fraction motile: EC50=0.40±0.07 µmol/L, nH= 4.4±3.9, sliding speed:   EC50=0.36±0.15 









1. Mogensen J, Murphy RT, Shaw T, Bahl A, Redwood C, Watkins H, Burke M, Elliott 
PM, McKenna WJ. Severe disease expression of cardiac troponin C and T mutations 
in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2004;44:2033-
2040. 
2. Kamisago M, Sharma SD, DePalma SR, Solomon S, Sharma P, Smoot L, Mullen MP, 
Woolf PK, Wigle ED, Seidman JG, Seidman CE, Jarcho J, Shapiro LR. Mutations in 
Sarcomere Protein Genes as a Cause of Dilated Cardiomyopathy. N Engl J Med. 
2000;343:1688-1696. 
3. Marston S, Hodgkinson J. Cardiac and skeletal myopathies:  Can genotype explain 
phenotype? J  Musc Res Cell motil. 2001;22:1-4. 
4. Robinson PJR, Mirza M, Knott A, Abdulrazzak H, Marston S, Watkins H, Redwood 
CS. Alterations in thin filament regulation induced by a human cardiac troponin T 
mutant that causes dilated cardiomyopathy are distinct from those induced by troponin 
T mutants that cause hypertrophic cardiomyopathy. J Biol Chem. 2002;277:40710-
40716. 
5. Marston S. Random walks with  thin filaments:   application of in vitro motility assay 
to the study of actomyosin regulation. J Musc Res Cell Motil. 2003;24:149-156. 
6. Knollmann BC, Potter JD. Altered Regulation of Cardiac Muscle Contraction by 
Troponin T Mutations that Cause Familial Hypertrophic Cardiomyopathy. Trends 
Cardiovasc Med. 2001;11:206-212. 
7. Chang AN, Harada K, Ackerman MJ, Potter JD. Functional consequences of 
hypertrophic and dilated cardiomyopathy-causing mutations in alpha-tropomyosin. J 
Biol Chem. 2005;280:34343-34349. 
8. Mirza M, Marston S, Willott R, Ashley C, Mogensen J, McKenna W, Robinson P, 
Redwood C, Watkins H. Dilated cardiomyopathy mutations in three thin filament 
regulatory proteins result in a common functional phenotype. J Biol Chem. 
2005;280:28498-28506. 
9. Robinson P, Griffiths PJ, Watkins H, Redwood CS. Dilated and hypertrophic 
cardiomyopathy mutations in troponin and alpha-tropomyosin have opposing effects 
on the calcium affinity of cardiac thin filaments. Circ Res. 2007;101:1266-1273. 
 23 
10. Du CK, Morimoto S, Nishii K, Minakami R, Ohta M, Tadano N, Lu QW, Wang YY, 
Zhan DY, Mochizuki M, Kita S, Miwa Y, Takahashi-Yanaga F, Iwamoto T, Ohtsuki 
I, Sasaguri T. Knock-In Mouse Model of Dilated Cardiomyopathy Caused by 
Troponin Mutation. Circ Res. 2007;101:185-194. 
11. Biesiadecki BJ, Kobayashi T, Walker JS, John Solaro R, de Tombe PP. The troponin 
C G159D mutation blunts myofilament desensitization induced by troponin I Ser23/24 
phosphorylation. Circ Res. 2007;100:1486-1493. 
12. Mirza M, Robinson P, Kremneva E, Copeland O, Nikolaeva O, Watkins H, Levitsky 
D, Redwood C, El-Mezgueldi M, Marston S. The effect of mutations in alpha 
tropomyosin (E40K and E54K), that cause familial dilated cardiomyopathy, on the 
regulatory mechanism of cardiac muscle thin filaments. J Biol Chem. 
2007;282:13487-13497. 
13. Rajan S, Ahmed RP, Jagatheesan G, Petrashevskaya N, Boivin GP, Urboniene D, 
Arteaga GM, Wolska BM, Solaro RJ, Liggett SB, Wieczorek DF. Dilated 
cardiomyopathy mutant tropomyosin mice develop cardiac dysfunction with 
significantly decreased fractional shortening and myofilament calcium sensitivity. 
Circ Res. 2007;101:205-214. 
14. Redwood C, Lohmann K, Bing W, Esoposito G, Elliott K, Abdulrazzak H, Knott A, 
Purcell I, Marston S, Watkins H. Investigation of a truncated troponin T that causes 
familial hypertrophic cardiomyopathy: Ca2+ regulatory properties of reconstituted 
thin filaments depend on the ratio of mutant to wild-type peptide. Circ Res. 
2000;86:1146-1152. 
15. Deng Y, Schmidtmann A, Redlich A, Westerdorf B, Jaquet K, Thieleczek R. Effects 
of Phosphorylation and Mutation R145G on Human Cardiac Troponin I Function. 
Biochemistry. 2001;40:14593-14602. 
16. Song W, Dyer E, Wells D, Harding S, Stuckey D, Carr C, Clarke C, Marston S. 
*Investigation of a mouse model of familial DCM with ACTC E361G mutation. J Mol 
Cell Cardiol. 2008;44:820-821. 
17. Marston S, Song W, Wells D, Harding S, Dyer E. *Studies of Transgenic Mice 
Expressing the E361G Mutation in Cardiac Muscle Actin that causes Dilated 
Cardiomyopathy. Biophys J. 2008;94:656. 
18. Knollmann BC, Blatt SA, Horton K, de Freitas F, Miller T, Bell M, Housmans PR, 
Weissman NJ, Morad M, Potter JD. Inotropic stimulation induces cardiac dysfunction 
 24 
in transgenic mice expressing a troponin T (I79N) mutation linked to familial 
hypertrophic cardiomyopathy. J Biol Chem. 2001;276:10039-10048. 
19. Preston LC, Ashley CC, Redwood CS. DCM troponin C mutation Gly159Asp blunts 
the response to troponin phosphorylation. Biochem Biophys Res Commun. 
2007;360:27-32. 
20. Jacques A, Briceno N, Messer A, Gallon C, Jalizadeh S, Garcia E, Kikonda-Kanda G, 
Goddard J, Harding S, Watkins H, Tsang V, McKenna W, Marston S. The molecular 
phenotype of human cardiac myosin associated with hypertrophic obstructive 
cardiomyopathy. Cardiovasc Res. 2008;79:481-491. 
21. Jacques A, Copeland O, Messer A, Gallon C, King C, McKenna W, Tsang V, Marston 
S. Myosin binding protein C phosphorylation in normal, hypertrophic and failing 
human heart muscle. J Mol Cell Cardiol. 2008;45:209-216. 
22. Nier V, Schultz I, Brenner B, Forssmann W, Raida M. Variability in the ratio of 
mutant to wildtype myosin heavy chain present in the soleus muscle of patients with 
familial hypertrophic cardiomyopathy. A new approach for the quantification of 
mutant to wildtype protein. FEBS Lett. 1999;461:246-252. 
23. Kohler J, Winkler G, Schulte T, McKenna W, Brenner B, Kraft T. Mutation of the 
myosin converter domain alters cross-bridge elasticity. Proc Natl Acad Sci USA. 
2002;99:3557-3562. 
24. Kirschner SE, Becker E, Antognozzi M, Kubis HP, Francino A, Navarro-Lopez F, 
Bit-Avragim N, Perrot A, Mirrakhimov MM, Osterziel KJ, McKenna WJ, Brenner B, 
Kraft T. Hypertrophic cardiomyopathy-related beta-myosin mutations cause highly 
variable calcium sensitivity with functional imbalances among individual muscle 
cells. Am J Physiol Heart Circ Physiol. 2005;288:H1242-1251. 
25. Kaski JP, Burch M, Elliott PM. Mutations in the cardiac Troponin C gene are a cause 
of idiopathic dilated cardiomyopathy in childhood. Cardiol Young. 2007;17:675-677. 
26. Preston LC, Lipscomb S, Robinson P, Mogensen J, McKenna WJ, Watkins H, Ashley 
CC, Redwood CS. Functional effects of the DCM mutant Gly159Asp Troponin C in 
skinned muscle fibres. Pflugers Arch. 2007;453:771-776. 
27. Messer AE, Jacques AM, Marston SB. Troponin phosphorylation and regulatory 
function in human heart muscle: Dephosphorylation of Ser23/24 on troponin I could 
account for the contractile defect in end-stage heart failure. J Mol Cell Cardiol. 
2007;42:247-259. 
 25 
28. Herron TJ, Rostkova E, Kunst G, Chaturvedi R, Gautel M, Kentish JC. Activation of 
Myocardial Contraction by the N-Terminal Domains of Myosin Binding Protein-C. 
Circ Res. 2006. 
29. van der Velden J, Klein LJ, van der Bijl M, Huybregts MA, Stooker W, Witkop J, 
Eijsman L, Visser CA, Visser FC, Stienen GJ. Force production in mechanically 
isolated cardiac myocytes from human ventricular muscle tissue. Cardiovasc Res. 
1998;38:414-423. 
30. Lim CC, Helmes MH, Sawyer DB, Jain M, Liao R. High-throughput assessment of 
calcium sensitivity in skinned cardiac myocytes. Am J Physiol Heart Circ Physiol. 
2001;281:H969-974. 
31. Purcell IF, Bing W, Marston SB. Functional analysis of human cardiac troponin by the 
in vitro motility assay: comparison of adult, foetal and failing hearts. Cardiovasc Res. 
1999;43:884-891. 
32. Monteiro PB, Lataro RC, Ferro JA, Reinach F. Functional alpha-tropomyosin 
produced in Escherichia coli. A dipeptide extension can substitute the amino-terminal 
acetyl group. J Biol Chem. 1994;269:10461-10466. 
33. Chang AN, Potter JD. Sarcomeric protein mutations in dilated cardiomyopathy. Heart 
Fail Rev. 2005;10:225-235. 
34. Robinson P, Mirza M, Knott A, Abdulrazzak H, Willott R, Marston S, Watkins H, 
Redwood C. Alterations in thin filament regulation induced by a human cardiac 
troponin T mutant that causes dilated cardiomyopathy are distinct from those induced 
by troponin T mutants that cause hypertrophic cardiomyopathy. J Biol Chem. 
2002;277:40710-40716. 
35. Houser SR, Margulies KB. Is depressed myocyte contractility centrally involved in 
heart failure? Circ Res. 2003;92:350-358. 
36. van der Velden J, Papp Z, Zaremba R, Boontje NM, de Jong JW, Owen VJ, Burton 
PB, Goldmann P, Jaquet K, Stienen GJ. Increased Ca2+-sensitivity of the contractile 
apparatus in end-stage human heart failure results from altered phosphorylation of 
contractile proteins. Cardiovasc Res. 2003;57:37-47. 
37. Dong W, Xing J, Ouyang Y, An J, Cheung HC. Structural kinetics of Cardiac troponin 
C mutants linked to familial hypertrophic and dilated cardiomyopathy in troponin 
complexes. J Biol Chem. 2008;283:3424-3432. 
38. Deng Y, Schmidtmann A, Kruse S, Filatov V, Heilmeyer LM, Jr., Jaquet K, 
Thieleczek R. Phosphorylation of human cardiac troponin I G203S and K206Q linked 
 26 
to familial hypertrophic cardiomyopathy affects actomyosin interaction in different 
ways. J Mol Cell Cardiol. 2003;35:1365-1374. 




Human heart muscle Skinned 
myocytes 









Motility of thin 
filaments Fraction motile EC50, µmol/L 0.14±0.05 0.05±0.03 3 0.36±0.07
 





Motility of thin 
filaments Fraction motile EC50, µmol/L 0.12±.01 0.07±0.01 2 0.56±0.09 





Motility of thin 
filaments Fraction motile EC50µmol/L 0.15±0.03 0.31±0.13 5 2.0±0.8 




(Mirza et al.) 
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